World

AstraZeneca leading the Covid-19 vaccine race; may get results quite early: WHO

Prashasti Awasthi Mumbai | Updated on June 27, 2020 Published on June 27, 2020

The World Health Organization said on Friday that AstraZeneca's experimental Covid-19 vaccine is the world’s leading candidate and reached the final stage in terms of development, Reuters reported.

AstraZeneca, a potential vaccine for coronavirus which is being developed by the researchers at the University of Oxford, has entered in large-scale, mid-stage human trials of the vaccine. This week, AstraZeneca signed its tenth supply-and-manufacturing deal.

"Certainly in terms of how advanced they are, the stage at which they are, they are I think probably the leading candidate," WHO chief scientist Soumya Swaminathan told a news conference.

"So it's possible they will have results quite early."

Swaminathan said Moderna's Covid-19 vaccine candidate was "not far behind" AstraZeneca's, among more than 200 candidates, 15 of which have entered clinical trials.

"We do know that Moderna's vaccine is also going to go into phase three clinical trials, probably from the middle of July, and so that vaccine candidate is not far behind," she said cited as saying in the Reuters report.

"But I think AstraZeneca certainly has a more global scope at the moment in terms of where they are doing and planning their vaccine trials."

WHO is in talks with various vaccine manufacture

The WHO is in talks with multiple Chinese manufacturers, including Sinovac, on potential vaccines, as well as with Indian researchers, Swaminathan said.

She also urged drugmakers to extend their support to the developers by collaborating on Covid-19 vaccine trials, similar to the WHO's ongoing Solidarity trial for drugs.

A WHO-led coalition fighting the pandemic on Friday asked the government and private sector donors to help raise $31.3 billion in the next 12 months to develop and deliver tests, treatments, and vaccines for the disease. The initiative is called the ACT-Accelerator.

Andrew Witty, Special Envoy for the ACT-Accelerator, said it was important to consider a "portfolio of research efforts" for vaccines.

"It's still very early days in this journey, we may be super lucky - which would be terrific - and have an early win," Witty said. "Even if it takes 12 to 18 months that would be without precedent, the world's fast development of a vaccine."

Published on June 27, 2020
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.